ALNY
Alnylam Pharmaceuticals, Inc.
Healthcare · in the Nasdaq-100
📍 Cambridge, United States · See it on the company map
The shape of the figures
Each spoke is one ratio. Further out means a higher figure than more of the index — not a better one. A high P/E or high debt sits far out too, so the size of the shape is not a score.
Drag to turn the shape. Tap or point at a dot to read the figure behind it.
The figures and what each one means are below. A hollow dot means the company doesn't report that figure.
Figures from the annual reports are unavailable right now — please try again in a minute.
Key figures, against the Nasdaq-100
Figures as of 11 Nov 2026, refreshed weekly
Each bar places this company among the Nasdaq-100 companies that report that figure. Further right means a higher figure — not a better one. Whether higher or lower suits you depends on what you are looking for, so the bars don't add up to a score.
Valuation
P/E ratio?
7.7x
The share price is 7.7 times the last twelve months' earnings per share.
P/E on average earnings?
—
No figure for this company.
Price / book
5.6x
The market values the company at 5.6 times the accounting value of its equity.
EV / EBIT?
34.3x
The company's value including its debt is 34.3 times its operating profit.
Free cash flow yield?
1.6%
Free cash flow equals 1.6% of the company's market value.
Profitability
Return on equity?
138.1%
Each 100 of shareholders' money produced 138.1 of net profit.
Return on assets?
9.5%
Each 100 of assets produced 9.5 of net profit.
Return on invested capital
31.1%
Each 100 invested by lenders and owners produced 31.1 of profit.
Operating margin?
15.5%
Of every 100 in sales, 15.5 was left as operating profit.
Debt
Debt / equity?
83.2%
Total debt equals 83% of shareholders' equity.
Net debt / EBITDA?
-0.6x
The company holds more cash than debt.
Interest cover
2.3x
Operating profit was 2.3 times the interest bill.
Growth
Revenue growth
117.9%
Latest revenue is 117.9% above the average of earlier reported years.
Earnings growth
—
No figure for this company.
⚠️ Not financial advice
This is a personal project, not professional investment research. The underlying market data may be delayed or incorrect. Nothing here is a recommendation to buy or sell any security. Always do your own research and consult a qualified professional before investing.
This tool is for informational and planning purposes only. It does not constitute financial, investment, tax or legal advice. Always consult a qualified professional before making financial decisions.